Altimmune (ALT) Financials

Altimmune’s latest quarter shows a company with a very large cash cushion, but still no meaningful product revenue and continued heavy operating losses. In Q1 2026, Altimmune reported $0 in revenue, an operating loss of $24.2 million, and a net loss of $22.6 million. The good news is that the balance sheet remains strong, with $334.7 million in total current assets, including $97.6 million in cash and equivalents and $233.9 million in short-term investments.

Over the last several years, the biggest trend is clear: Altimmune remains a development-stage biotech that is spending aggressively on research and development while relying on its cash reserves and periodic equity issuance to fund operations. Revenue has been negligible across the period shown, while losses have generally stayed in the low-to-mid $20 million range per quarter.

• Cash and short-term investments remain substantial at $331.5 million combined in Q1 2026, providing meaningful runway.
• Total liabilities were only $51.6 million in Q1 2026, which is modest relative to the company’s cash and investments.
• Operating cash burn improved versus prior quarters, with Q1 2026 operating cash outflow of $20.9 million compared with $19.4 million in Q4 2025 and $27.1 million in Q3 2025.
• Interest and investment income helped offset losses, contributing $2.9 million in Q1 2026.
• The company has kept capital expenditures very low, with minimal spending on property and equipment.
• Q1 2026 financing inflows were driven by $79.3 million of common equity issuance, reinforcing reliance on capital markets.
• Quarterly operating revenue has remained minimal, with only token revenue amounts in prior periods and $0 in Q1 2026.
• R&D spending remains high at $16.2 million in Q1 2026, which is typical for a clinical-stage biotech but continues to pressure earnings.
• The company reported a net loss of $22.6 million in Q1 2026, extending a long pattern of quarterly losses.
• Share count has risen significantly over time, indicating meaningful dilution from repeated equity raises.

Looking at the multi-year trend, Altimmune’s balance sheet has improved, but through financing rather than operations. Cash and investments have grown sharply from early 2025 into Q1 2026, largely because of equity issuance. For example, common stock on the balance sheet increased from $728.1 million in Q1 2025 to $961.3 million in Q1 2026, reflecting the cumulative effect of share issuance. At the same time, retained earnings remain deeply negative at $(672.0) million, underscoring the company’s long history of losses.

From an investor perspective, the key takeaway is runway versus execution. Altimmune appears well-funded for the near term, and its liquidity position is much stronger than its liabilities. However, the company is still not generating meaningful revenue, and the business continues to consume cash every quarter. Until there is clearer commercial traction or a major clinical milestone, the stock will likely remain dependent on pipeline progress and investor sentiment rather than financial performance.